Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia

Bone Marrow Transplantation

Volumn 34, Issue 12, 2004, Pages 1047-1050

  Koldehoff, M ^a   Beelen, D W ^a   Trenschel, R ^a   Steckel, N K ^a   Peceny, R ^a   Ditschkowski, M ^a   Ottinger, H ^a   Elmaagacli, Ahmet H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

aCML; BMT; HSCT; Outcome; PBSCT

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BLOOD COMPATIBILITY; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; INFECTION COMPLICATION; ISOGRAFT; LEUKOCYTE COUNT; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; TOXOPLASMOSIS; TREATMENT OUTCOME; TWINS; VARIABLE NUMBER OF TANDEM REPEAT; WHOLE BODY RADIATION;

ADULT; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME;

EID: 11144286569     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704686     Document Type: Article

References (21)

1. Vardiman JW, Brunning RD, Harris NL. Chronic myeloproliferative disease. In: Jaffe ES, Harris NL, Stein H and Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press: Lyon, 2001, pp 15-44.
2. Shtalrid M, Talpaz M, Blick M et al. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol 1988; 6 1569-1575.
3. Bennett JM, Catovsky D, Daniel MT et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87: 746-754.
4. Galton DA. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukemia. Leuk Lymphoma 1992; 7: 343-350.
5. Aurich J, Duchayne E, Huguet-Rigal F et al. Clinical, morphological, cytogenetic and molecular aspects of series of Ph-negative chronic myeloid leukemias. Hematol Cell Ther 1998; 40: 149-158.
6. Vardiman JW, Imbert M, Pierre R et al. Atypical chronic myeloid leukaemia. In: Jaffe ES, Harris NL, Stein H and Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press: Lyon, 2001, pp 53-54.
7. Montefusco E, Alimena G, Lo Coco F et al. Ph-negative and bcr-abl negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 1992; 65: 17-21.
8. Kurzrock R, Kantarjian HM, Shtalrid M et al. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with distinct clinical course. Blood 1990; 75: 445-452.
9. Oscier DG. Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome. Br J Haematol 1996; 92: 582-586.
10. Costello R, Sainty D, Lafage-Pochitaloff M, Gabert J. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma 1997; 25: 225-232.
11. Kurzrock R, Bueso-Ramos CE, Kantarjian H et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19: 2915-2926.
12. Hernandez JM, del Canizo MC, Cuneo A et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000; 11: 441-444.
13. Kapaun P, Kabisch H, Held KR et al. Atypical chronic myelogenous leukemia in a patient with trisomy 8 mosaicisin syndrome. Ann Hematol 1993; 66: 57-58.
14. Elmaagacli AH, Runkel K, Steckel N et al. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Bone Marrow Transplant 2001; 27 809-815.
15. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895-902.
16. Elmaagacli AH, Peceny R, Steckel N et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T cell add-back compared to unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101: 446-453.
17. Alizadeh M, Bernard M, Danic B et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618-4625.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Cortes J, Giles F, O'Brien S et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003; 97: 2760-2766.
20. Elmaagacli AH, Basoglu S, Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared to bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130-1135.
21. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic leukemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092.